Eu­ro­pean Com­mis­sion clears As­traZeneca's $39B bid for Alex­ion and a fu­ture in rare dis­eases. Now there's just a fi­nal hur­dle

As­traZeneca has cleared the penul­ti­mate hur­dle be­fore of­fi­cial­ly com­plet­ing its $39 bil­lion ac­qui­si­tion of Alex­ion.

The Eu­ro­pean Com­mis­sion has giv­en its bless­ing to the pro­posed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER